Back

Estrogen receptor-positive cell line xenograft models recapitulate metastatic dissemination and endocrine response of invasive lobular breast carcinoma

Tasdemir, N.; Savariau, L.; Scott, J.; Latoche, J.; Biery, K.; Li, Z.; Bossart, E.; Sreekumar, S.; Brown, D.; Wang, S.; Watters, R.; Nasrazadani, A.; Qin, Y.; Cao, Y.; Chen, F.; Tseng, G.; Castro, C.; Anderson, C. J.; Atkinson, J.; Hooda, J.; Lucas, P. C.; Davidson, N.; LEE, A. V.; Oesterreich, S.

2026-03-18 cancer biology
10.64898/2026.03.17.712396 bioRxiv
Show abstract

Invasive lobular breast carcinoma (ILC), the most common special histological subtype of breast cancer, is characterized by nearly universal expression of estrogen receptor alpha (ER) and unique sites of metastases, neither of which is fully recapitulated by genetically engineered mouse models. Using reporter-labeled ILC mouse xenografts, herein we used mammary fat pad, tail vein and intracardiac orthotopic growth to analyze spontaneous and experimental metastasis and gene expression. We observed ER-positive primary tumors with single-file histology and collagen deposition, and spontaneous metastasis from the mammary fat pad to bones, ovaries, and brain including the leptomeninges, thereby closely mirroring the growth and metastatic spread of human ILC. Brain metastases showed strong ER staining, confirmed by sequencing analyses which identified estrogen signaling as top activated pathway, and the lesions exhibited robust response to endocrine therapy. In summary, we report endocrine responsive mammary fat pad, tail vein and intracardiac xenografts that faithfully demonstrate unique ILC features and can serve as invaluable pre-clinical translational platforms for validating candidate ILC genetic drivers and testing novel therapeutics.

Matching journals

The top 8 journals account for 50% of the predicted probability mass.

1
Breast Cancer Research
32 papers in training set
Top 0.1%
22.3%
2
Cancers
200 papers in training set
Top 0.9%
6.3%
3
npj Breast Cancer
18 papers in training set
Top 0.1%
4.8%
4
Cancer Research
116 papers in training set
Top 0.4%
4.8%
5
Frontiers in Oncology
95 papers in training set
Top 0.9%
4.3%
6
Genome Medicine
154 papers in training set
Top 2%
3.6%
7
Scientific Reports
3102 papers in training set
Top 38%
3.6%
8
Nature Communications
4913 papers in training set
Top 42%
3.2%
50% of probability mass above
9
International Journal of Cancer
42 papers in training set
Top 0.3%
3.0%
10
Cell Reports Medicine
140 papers in training set
Top 2%
2.6%
11
PLOS ONE
4510 papers in training set
Top 47%
2.3%
12
The Journal of Pathology
22 papers in training set
Top 0.1%
1.9%
13
Oncogene
76 papers in training set
Top 0.9%
1.9%
14
Cell Reports
1338 papers in training set
Top 22%
1.9%
15
Annals of Oncology
13 papers in training set
Top 0.4%
1.8%
16
Cancer Research Communications
46 papers in training set
Top 0.5%
1.7%
17
BMC Cancer
52 papers in training set
Top 1%
1.7%
18
Clinical Cancer Research
58 papers in training set
Top 1%
1.7%
19
Cancer Medicine
24 papers in training set
Top 0.9%
1.5%
20
eLife
5422 papers in training set
Top 45%
1.5%
21
Laboratory Investigation
13 papers in training set
Top 0.1%
1.1%
22
Disease Models & Mechanisms
119 papers in training set
Top 2%
0.9%
23
Molecular Cancer Research
42 papers in training set
Top 0.6%
0.9%
24
Proceedings of the National Academy of Sciences
2130 papers in training set
Top 41%
0.9%
25
Communications Biology
886 papers in training set
Top 19%
0.9%
26
Cancer Letters
32 papers in training set
Top 0.8%
0.7%
27
British Journal of Cancer
42 papers in training set
Top 2%
0.7%
28
eBioMedicine
130 papers in training set
Top 4%
0.7%
29
Translational Oncology
18 papers in training set
Top 0.5%
0.7%
30
Molecular Oncology
50 papers in training set
Top 1%
0.6%